Replimune (REPL) 10-Q 4 Feb 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2020	Feb. 01, 2021
Cover [Abstract]
Entity Registrant Name	Replimune Group, Inc.
Entity Central Index Key	0001737953
Document Type	10-Q
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		46,493,467
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	REPL
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Current assets:
Cash and cash equivalents	$ 324,475	$ 59,500
Short-term investments	168,797	109,055
Research and development incentives receivable	2,121	2,962
Prepaid expenses and other current assets	4,035	2,734
Total current assets	499,428	174,251
Property, plant and equipment, net	7,166	6,860
Restricted cash	1,636	1,636
Right-to-use asset-operating leases	5,839	4,425
Right-to-use asset-financing leases	45,129	46,925
Total assets	559,198	234,097
Current liabilities:
Accounts payable	2,350	3,434
Accrued expenses and other current liabilities	7,234	5,156
Operating lease liabilities, current	965	873
Financing lease liabilities, current	2,469	2,411
Total current liabilities	13,018	11,874
Long term debt, net of debt discount		9,801
Operating lease liabilities, non-current	5,170	3,737
Financing lease liabilities, non-current	24,815	24,967
Total liabilities	43,003	50,379
Commitments and contingencies (Note 12)
Stockholders' Equity
Common stock, $0.001 par value; 150,000,000 shares authorized as of December 31, 2020 and March 31, 2020; 46,384,675 and 36,668,743 shares issued and outstanding as of December 31, 2020 and March 31, 2020, respectively	46	37
Additional paid-in capital	687,934	296,961
Accumulated deficit	(171,669)	(112,298)
Accumulated other comprehensive loss	(116)	(982)
Total stockholders' equity	516,195	183,718
Total liabilities and stockholders' equity	$ 559,198	$ 234,097

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2020	Mar. 31, 2020
CONDENSED CONSOLIDATED BALANCE SHEETS
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	46,384,675	36,668,743
Common stock, outstanding	46,384,675	36,668,743

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Research and development	$ 14,322	$ 11,948	$ 40,529	$ 27,573
General and administrative	5,953	4,716	17,242	12,240
Total operating expenses	20,275	16,664	57,771	39,813
Loss from operations	(20,275)	(16,664)	(57,771)	(39,813)
Other income (expense):
Research and development incentives	550	951	1,991	2,192
Investment income	116	550	821	1,804
Interest expense on finance lease liability	(560)	(834)	(1,683)	(1,029)
Interest expense on debt obligations	(247)		(817)
Loss on extinguishment of debt	(913)		(913)
Other income (expense)	(454)	(192)	(999)	10
Total other income (expense), net	(1,508)	475	(1,600)	2,977
Net loss attributable to common stockholders	$ (21,783)	$ (16,189)	$ (59,371)	$ (36,836)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.44)	$ (0.46)	$ (1.34)	$ (1.13)
Weighted average common shares outstanding, basic and diluted (in shares)	49,382,213	34,877,944	44,436,680	32,742,148

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Net loss	$ (21,783)	$ (16,189)	$ (59,371)	$ (36,836)
Other comprehensive loss:
Foreign currency translation gain (loss)	548	408	1,162	8
Net unrealized gain (loss) on short-term investments, net of tax	(53)	(25)	(296)
Comprehensive loss	$ (21,288)	$ (15,806)	$ (58,505)	$ (36,828)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Common stockATM sales	Common stockFollow-on public offering	Common stock	Additional paid-in capitalATM sales	Additional paid-in capitalFollow-on public offering	Additional paid-in capital	Accumulated deficitImpact of adoption of ASC 842	Accumulated deficit	Accumulated other comprehensive loss	Impact of adoption of ASC 842	ATM sales	Follow-on public offering	Total
Balance at Mar. 31, 2019			$ 32			$ 198,645		$ (59,766)	$ (1,055)				$ 137,856
Balance (in shares) at Mar. 31, 2019			31,656,950
Increase (decrease) in Stockholders' Equity
Foreign currency translation adjustment									(182)				(182)
Unrealized loss on short-term investments									65				65
Exercise of stock options						18							18
Exercise of stock options (in shares)			6,751
Stock-based compensation expense						1,810							1,810
Impact of adoption of ASC 842							$ 93			$ 93
Net loss								(9,508)					(9,508)
Balance at Jun. 30, 2019			$ 32			200,473		(69,181)	(1,172)				130,152
Balance (in shares) at Jun. 30, 2019			31,663,701
Balance at Mar. 31, 2019			$ 32			198,645		(59,766)	(1,055)				137,856
Balance (in shares) at Mar. 31, 2019			31,656,950
Increase (decrease) in Stockholders' Equity
Foreign currency translation adjustment													8
Net loss													(36,836)
Balance at Dec. 31, 2019			$ 37			295,084		(96,509)	(1,047)				197,565
Balance (in shares) at Dec. 31, 2019			36,645,650
Balance at Mar. 31, 2019			$ 32			198,645		(59,766)	(1,055)				137,856
Balance (in shares) at Mar. 31, 2019			31,656,950
Increase (decrease) in Stockholders' Equity
Issuance of common stock, net of issuance costs and underwriter fees (in shares)											287,559
Balance at Mar. 31, 2020			$ 37			296,961		(112,298)	(982)				183,718
Balance (in shares) at Mar. 31, 2020			36,668,743
Balance at Jun. 30, 2019			$ 32			200,473		(69,181)	(1,172)				130,152
Balance (in shares) at Jun. 30, 2019			31,663,701
Increase (decrease) in Stockholders' Equity
Foreign currency translation adjustment									(218)				(218)
Unrealized loss on short-term investments									(40)				(40)
Exercise of stock options						105							105
Exercise of stock options (in shares)			55,645
Stock-based compensation expense						1,781							1,781
Net loss								(11,139)					(11,139)
Balance at Sep. 30, 2019			$ 32			202,359		(80,320)	(1,430)				120,641
Balance (in shares) at Sep. 30, 2019			31,719,346
Increase (decrease) in Stockholders' Equity
Issuance of prefunded warrants to purchase common stock, net of issuance costs						28,145							28,145
Issuance of common stock, net of issuance costs and underwriter fees		$ 5		$ 4,431	$ 57,448						$ 4,431	$ 57,453
Issuance of common stock, net of issuance costs and underwriter fees (in shares)	287,559	4,516,561
Foreign currency translation adjustment									408				408
Unrealized loss on short-term investments									(25)				(25)
Exercise of stock options						357							357
Exercise of stock options (in shares)			122,184
Stock-based compensation expense						2,344							2,344
Net loss								(16,189)					(16,189)
Balance at Dec. 31, 2019			$ 37			295,084		(96,509)	(1,047)				197,565
Balance (in shares) at Dec. 31, 2019			36,645,650
Balance at Mar. 31, 2020			$ 37			296,961		(112,298)	(982)				183,718
Balance (in shares) at Mar. 31, 2020			36,668,743
Increase (decrease) in Stockholders' Equity
Issuance of prefunded warrants to purchase common stock, net of issuance costs						32,900							32,900
Issuance of common stock, net of issuance costs and underwriter fees			$ 3			74,879							74,882
Issuance of common stock, net of issuance costs and underwriter fees (in shares)			3,478,261
Foreign currency translation adjustment									(12)				(12)
Unrealized loss on short-term investments									(196)				(196)
Exercise of stock options						1,547							1,547
Exercise of stock options (in shares)			133,416
Stock-based compensation expense						2,468							2,468
Net loss								(17,493)					(17,493)
Balance at Jun. 30, 2020			$ 40			408,755		(129,791)	(1,190)				277,814
Balance (in shares) at Jun. 30, 2020			40,280,420
Balance at Mar. 31, 2020			$ 37			296,961		(112,298)	(982)				183,718
Balance (in shares) at Mar. 31, 2020			36,668,743
Increase (decrease) in Stockholders' Equity
Issuance of common stock, net of issuance costs and underwriter fees (in shares)											0
Foreign currency translation adjustment													1,162
Unrealized loss on short-term investments													$ (296)
Exercise of stock options (in shares)													612,671
Net loss													$ (59,371)
Balance at Dec. 31, 2020			$ 46			687,934		(171,669)	(116)				516,195
Balance (in shares) at Dec. 31, 2020			46,384,675
Balance at Jun. 30, 2020			$ 40			408,755		(129,791)	(1,190)				277,814
Balance (in shares) at Jun. 30, 2020			40,280,420
Increase (decrease) in Stockholders' Equity
Foreign currency translation adjustment									626				626
Unrealized loss on short-term investments									(47)				(47)
Exercise of stock options						291							291
Exercise of stock options (in shares)			31,852
Stock-based compensation expense						2,801							2,801
Net loss								(20,095)					(20,095)
Balance at Sep. 30, 2020			$ 40			411,847		(149,886)	(611)				261,390
Balance (in shares) at Sep. 30, 2020			40,312,272
Increase (decrease) in Stockholders' Equity
Issuance of prefunded warrants to purchase common stock, net of issuance costs						58,750							58,750
Issuance of common stock, net of issuance costs and underwriter fees			$ 5			211,220							211,225
Issuance of common stock, net of issuance costs and underwriter fees (in shares)			5,625,000
Foreign currency translation adjustment									548				548
Unrealized loss on short-term investments									(53)				(53)
Exercise of stock options			$ 1			3,068							3,069
Exercise of stock options (in shares)			447,403
Stock-based compensation expense						3,049							3,049
Net loss								(21,783)					(21,783)
Balance at Dec. 31, 2020			$ 46			$ 687,934		$ (171,669)	$ (116)				$ 516,195
Balance (in shares) at Dec. 31, 2020			46,384,675

CONSOLIDATED STATEMENTS OF ST_2

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Prefunded warrants
Issuance costs and underwriter fees	$ 3,750	$ 2,100	$ 1,797
Common stock
Issuance costs and underwriter fees	$ 13,775	$ 5,117
Common stock | Follow-on public offering
Issuance costs and underwriter fees			$ 4,017

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (59,371)	$ (36,836)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	8,318	5,935
Depreciation and amortization	1,217	191
Noncash interest expense	181	94
Loss on extinguishment of debt	913
Net amortization of premiums and discounts on short-term investments	841	(899)
Changes in operating assets and liabilities:
Research and development incentives receivable	1,078	(2,184)
Prepaid expenses and other current assets	(1,238)	(1,520)
Operating lease, right-of-use-asset	341	421
Finance lease, right-of-use-asset	1,795	666
Long term prepaid rent		(14,051)
Accounts payable	(1,018)	(2,585)
Accrued expenses and other current liabilities	1,919	1,781
Operating lease liabilities	(237)	(303)
Net cash used in operating activities	(45,261)	(49,290)
Cash flows from investing activities:
Purchases of property, plant and equipment	(1,622)	(5,202)
Purchase of short-term investments	(225,029)	(119,611)
Proceed from sales and maturities of short-term investments	164,148	111,739
Net cash provided by (used in) investing activities	(62,503)	(13,074)
Cash flows from financing activities:
Proceeds from issuance of common stock in follow-on public offering, net of underwriting fees and discounts	286,107	57,453
Proceeds from issuance of prefunded warrants to purchase common stock, net of underwriting fees and discounts	91,650	28,145
Proceeds from issuance of common stock through ATM sales		4,431
Proceeds from long-term debt		10,000
Principal payment of long-term debt	(10,000)
Payment of long-term debt extinguishment costs	(795)
Payment of issuance costs	(100)	(355)
Principal payment of finance lease obligation	(92)	(22)
Exercise of stock options	4,907	480
Net cash provided by financing activities	371,677	100,132
Effect of exchange rate changes on cash, cash equivalents and restricted cash	1,062	(20)
Net increase (decrease) in cash, cash equivalents and restricted cash	264,975	37,748
Cash, cash equivalents and restricted cash at beginning of period	61,136	26,890
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	636	282
Supplemental disclosure of non-cash investing and financing activities:
Net unrealized gain (loss) on short-term investments	296
Purchases of property and equipment included in accounts payable	99
Lease assets obtained in exchange for new financing lease liabilities		48,224
Lease assets obtained in exchange for new operating lease liabilities	$ 1,580	$ 5,152

Nature of the business

Nature of the business	9 Months Ended
	Dec. 31, 2020
Nature of the business
Nature of the business	1. Nature of the business Replimune Group, Inc. (the “Company”) is a clinical‑stage biotechnology company focused on the development of oncolytic immunotherapies to treat cancer. Replimune Group, Inc., whose predecessor was founded in 2015, is the parent company of its wholly owned, direct and indirect subsidiaries: Replimune Limited ("Replimune UK"); Replimune, Inc. ("Replimune US"); Replimune Securities Corporation; and Replimune (Ireland) Limited. The Company is subject to risks and uncertainties common to early‑stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. Basis of presentation The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net losses of $21,783 and $16,189 for the three months ended December 31, 2020 and 2019, respectively and net losses of $59,371and $36,836 for the nine months ended December 31, 2020 and 2019, respectively. In addition, as of December 31, 2020, the Company had an accumulated deficit of $171,669. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the consolidated financial statements. Impact of the COVID-19 coronavirus In December 2019, a novel strain of coronavirus, which causes the disease known as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 coronavirus has spread globally. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic and the U.S. government imposed travel restrictions on travel between the United States, Europe and certain other countries. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society, which has resulted, and will likely continue to result, in significant disruptions to the global economy as well as businesses and capital markets around the world. In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company has taken precautionary measures, including implementing work-from-home policies for the Company’s employees, other than those in its laboratory, those performing manufacturing functions and certain other employees as deemed appropriate from time to time. For those employees, the Company has implemented stringent safety measures designed to comply with applicable federal, state and local guidelines instituted in response to the COVID-19 pandemic. The Company has taken these and other precautionary steps while maintaining business continuity in order to continue to progress its programs. While there has been no prolonged material disruption to the Company’s business to date, the impact of the virus, including work-from-home policies, may negatively impact productivity, disrupt the Company’s business, and delay its preclinical research and clinical trial activities and its development program timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct its business in the ordinary course. Other impacts to the Company’s business may include temporary closures of its suppliers and disruptions or restrictions on its employees’ ability to travel. Any prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s preclinical research and clinical trial activities, financial condition and results of operations, including its ability to obtain financing.

Summary of significant accounti

Summary of significant accounting policies	9 Months Ended
	Dec. 31, 2020
Summary of significant accounting policies
Summary of significant accounting policies	2. Summary of significant accounting policies Principles of consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Replimune UK, Replimune US, Replimune Securities Corporation and Replimune (Ireland) Limited after elimination of all intercompany accounts and transactions. Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock‑based awards. The Company bases its estimates on historical experience, known trends and other market‑specific or other relevant factors that it believes to be reasonable under the circumstances. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including, expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions. Unaudited interim financial information The accompanying consolidated balance sheet as of December 31, 2020, the consolidated statements of operations, of comprehensive loss and of stockholders’ equity for the three and nine months ended December 31, 2020 and 2019 and the consolidated statements of cash flows for the nine months ended December 31, 2020 and 2019 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of December 31, 2020 and the results of its operations for the three and nine months ended December 31, 2020 and 2019 and its cash flows for the nine months ended December 31, 2020 and 2019. The financial data and other information disclosed in these consolidated notes related to the three and nine months ended December 31, 2020 and 2019 are unaudited. The results for the three and nine months ended December 31, 2020 are not necessarily indicative of results to be expected for the year ending March 31, 2021, any other interim periods or any future year or period. The financial information included herein should be read in conjunction with the financial statements and notes in the Company's Annual Report on Form 10-K for the year ended March 31, 2020. During the three and nine months ended December 31, 2020, there have been no changes to the Company’s significant accounting policies as described in the Company's Annual Report on Form 10-K for the year ended March 31, 2020 which was filed with the Securities and Exchange Commission on June 3, 2020, except as described below. Recently adopted accounting pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). The amendments in this ASU require certain existing disclosure requirements in Topic 820 to be modified or removed, and certain new disclosure requirements to be added to the Topic. In addition, this ASU allows entities to exercise more discretion when considering fair value measurement disclosures. The Company adopted ASU 2018-13 on April 1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company's consolidated financial statements. In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”), which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in Topic 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. The standard adds unit-of-account guidance in Topic 808 to align with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606, and requires that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, including adoption in any interim period for public business entities for periods in which financial statements have not been issued. Amendments in the standard should be applied retrospectively to the date of initial application of Topic 606, but entities may elect to apply the amendments in this Update retrospectively either to all contracts or only to contracts that are not completed at the date of initial application of Topic 606, and should disclose the election. An entity may also elect to apply the practical expedient for contract modifications that is permitted for entities using the modified retrospective transition method in Topic 606. The Company adopted ASU 2018-18 on April 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company's consolidated financial statements. Recently issued accounting pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments- Credit Losses (Topic 326). The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments – Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326), which provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. The standard is effective for fiscal years and interim periods beginning after December 15, 2022. Early adoption is permitted for all periods beginning after December 15, 2018. The adoption of ASU 2016-13 is not expected to have a material impact on the Company's consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12 ), as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The standard is effective for fiscal years and interim periods beginning after December 15, 2020. The Company is currently evaluating the impact of this new guidance on its financial statements and related disclosures but does not expect the adoption of ASU 2019-12 to have a material impact on the Company's consolidated financial statements.

Fair value of financial assets

Fair value of financial assets and liabilities	9 Months Ended
	Dec. 31, 2020
Fair value of financial assets and liabilities
Fair value of financial assets and liabilities	3. Fair value of financial assets and liabilities The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets Money market funds $ — $ 276,076 $ — $ 276,076 US Government Agency bonds — 63,295 — 63,295 US Treasury bonds — 105,502 — 105,502 $ — $ 444,873 $ — $ 444,873 Fair Value Measurements as of March 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets Money market funds $ — $ 36,712 $ — $ 36,712 Commercial paper — 21,884 — 21,884 US Treasury bonds — 35,810 — 35,810 US Government Agency bonds — 15,295 — 15,295 Corporate debt securities — 36,066 — 36,066 $ — $ 145,767 $ — $ 145,767 The underlying securities held in the money market funds held by the Company are all government backed securities. During the three and nine months ended December 31, 2020 and 2019, there were no transfers between levels. Valuation of cash equivalents and short-term investments Money market funds, commercial paper, U.S. Treasury bonds, U.S. Government Agency bonds and corporate debt securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. Cash equivalents consisted of money market funds at December 31, 2020 and March 31, 2020.

Short-term investments

Short-term investments	9 Months Ended
	Dec. 31, 2020
Short-term investments
Short-term investments	4. Short‑term investments Short‑term investments by investment type consisted of the following: December 31, 2020 Gross Gross Amortized unrealized unrealized cost gains losses Fair value US Government agency bonds $ 63,284 $ 11 $ — $ 63,295 US Treasury bonds 105,487 17 (2) 105,502 $ 168,771 $ 28 $ (2) $ 168,797 March 31, 2020 Gross Gross Amortized unrealized unrealized cost gains losses Fair value Commercial paper $ 21,818 $ 66 $ — $ 21,884 US Government agency bonds 15,217 78 — 15,295 US Treasury bonds 35,590 220 — 35,810 Corporate debt securities 36,107 24 (65) 36,066 $ 108,732 $ 388 $ (65) $ 109,055

Property, plant and equipment,

Property, plant and equipment, net	9 Months Ended
	Dec. 31, 2020
Property, plant and equipment, net
Property, plant and equipment, net	5. Property, plant and equipment, net Property, plant and equipment, net consisted of the following: December 31, March 31, 2020 2020 Construction in progress $ 1,363 $ 1,217 Plant and laboratory equipment 4,784 3,669 Leasehold improvements 785 532 Computer equipment 1,667 1,658 Office equipment 721 721 9,320 7,797 Less: Accumulated depreciation and amortization (2,154) (937) $ 7,166 $ 6,860 Depreciation and amortization expense was $402 and $1,217 for the three and nine months ended December 31, 2020, respectively, and $107 and $191 for the three and nine months ended December 31, 2019, respectively. Depreciation and amortization expense are recorded within research and development and general and administrative expenses in the consolidated statement of operations.

Accrued expenses and other curr

Accrued expenses and other current liabilities	9 Months Ended
	Dec. 31, 2020
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities	6. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consisted of the following: December 31, March 31, 2020 2020 Accrued research and development costs $ 3,714 $ 2,009 Accrued compensation and benefits costs 2,638 2,065 Accrued professional fees 363 779 Other 519 303 $ 7,234 $ 5,156

Long-term debt

Long-term debt	9 Months Ended
	Dec. 31, 2020
Long-term debt
Long-term debt	7. Long-term debt Long-term debt consisted of the following: December 31, March 31, 2020 2020 Principal amount of long-term debt $ — $ 10,000 Unamortized debt discount — (199) Long-term debt, net of discount $ — $ 9,801 Hercules Loan Agreement On August 8, 2019, (the “Closing Date”) the Company and certain of its affiliates entered into a Loan and Security Agreement (as amended, the “Hercules Loan Agreement”) with Hercules Capital, Inc. (“Hercules”) pursuant to which Hercules agreed to make available to the Company a secured term loan facility in the amount of $30,000 (the “Term Loan Facility”), subject to certain terms and conditions. The Company borrowed $10,000 under the Hercules Loan Agreement in one advance as a single tranche term loan on the Closing Date upon which the Company paid a $225 facility charge and incurred $130 in additional closing and legal fees. On June 1, 2020, the Company entered into the First Amendment to the Hercules Loan Agreement (the "Hercules First Amendment"), to, among other things, increase the aggregate principal amount of the secured term loan facility from $30,000 to $40,000. Pursuant to the Hercules First Amendment, subject to the achievement of certain milestones, the Company could have borrowed three tranches of up to $10,000 between October 1, 2020 and December 15, 2020, July 1, 2020 and June 30, 2021, and July 1, 2021 and December 15, 2021, respectively. The Company incurred $100 in additional closing and legal fees in connection with Hercules First Amendment which were capitalized and will be amortized as part of the effective yield. On December 15, 2020, the Company entered into a Payoff Letter with respect to the Hercules Loan Agreement, which resulted in a loss on extinguishment of debt of $913 including both cash and non-cash expense. Pursuant to the Payoff Letter, the Company paid a total of $10,839 to Hercules, representing $10,000 in outstanding principal, $495 end of term charge, $300 early termination fee due and $44 in accrued interest owed to Hercules under the Hercules Loan Agreement. In connection with the execution of the Payoff Letter and the repayment of the Company’s outstanding obligations under the Hercules Loan Agreement, the Hercules Loan Agreement and the related loan documents were terminated. The Term Loan Facility was secured by substantially all of the Company’s assets, but excluding its intellectual property, and subject to certain exceptions and exclusions. All liens on the Company's assets held by Hercules were released in connection with the execution of the Payoff Letter. In connection with entering into the Hercules Loan Agreement, the Company paid Hercules $355 of upfront fees, including closing costs and legal fees associated with entering into the agreement, which were recorded as a debt discount. In connection with entering into the Hercules First Amendment, the Company paid $100 of upfront fees, including closing costs and legal fees associated with entering into the amendment, which were recorded as debt discount. The debt discount is reflected as a reduction of the carrying value of long-term debt on the Company’s consolidated balance sheet and is being amortized to interest expense over the term of the loan using the effective interest method. The Company recognized aggregate interest expense under the Hercules Loan Agreement of $247 and $817 during the three and nine months ended December 31, 2020, respectively, which included non-cash interest expense of $55 and $181 for the three and nine months ended December 31, 2020, respectively. Non-cash interest expense related to the amortization of the debt discount of $26 and $82 and the accretion of the final payment of $29 and $99 for the three and nine months ended December 31, 2020, respectively.

Stockholders' equity

Stockholders' equity	9 Months Ended
	Dec. 31, 2020
Stockholders' equity
Stockholders' equity	8. Stockholders’ equity Common stock As of December 31, 2020 and March 31, 2020, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue up to 150,000,000 shares of common stock, par value $0.001 per share. As of December 31, 2020 and March 31, 2020, the Company had reserved 14,753,921 and 10,449,033 shares of common stock for the exercise of outstanding stock options, the number of shares remaining available for grant under the Company's 2018 Omnibus Incentive Compensation Plan and the Company's Employee Stock Purchase Plan (see Note 9) and the exercise of the outstanding warrants to purchase shares of common stock, respectively. Undesignated preferred stock As of December 31, 2020, the Company’s certificate of incorporation, as amended and restated, authorized the Company to issue up to 10,000,000 shares of undesignated preferred stock, par value $0.001 per share. There were no undesignated preferred shares issued or outstanding as of December 31, 2020. Convertible preferred stock and preferred stock warrants The Company has issued series seed convertible preferred stock (the “series seed preferred stock”), series A convertible preferred stock (the “series A preferred stock”) and series B convertible preferred stock (the “series B preferred stock”). The series seed preferred stock, series A preferred stock and series B preferred stock are collectively referred to as the “preferred stock.” In connection with the closing of the Company's initial public offering (the "IPO") in 2018, the preferred stock converted into 19,157,360 shares of common stock on a 1:9.94688 basis. There was no preferred stock outstanding as of December 31, 2020 and March 31, 2020. In connection with the issuance of the series seed preferred stock, the Company issued to the holders of the series seed preferred stock warrants for the purchase of 50,000 shares of series seed preferred stock, which became fully vested and exercisable in the year of issuance. The warrants to purchase shares of series seed preferred stock were issued at an exercise price of $10.00 per share and expire on the earlier of September 16, 2025 or a qualified change of control event. In connection with the closing of the IPO, the series seed preferred stock warrants became exercisable for 497,344 shares of common stock and the exercise price was adjusted to $1.01 per share. Upon the closing of the IPO, the series seed preferred stock warrants were reclassified to stockholders' equity. The warrants to purchase 497,344 shares of common stock remain outstanding as of December 31, 2020. ATM program In August 2019, the Company entered into a Sales Agreement (as amended, the “2019 Sales Agreement”) with SVB Leerink LLC (the “Agent”), pursuant to which the Company could sell, from time to time, at its option, up to an aggregate amount of $75,000 of shares of the Company’s common stock, $0.001 par value per share, through the Agent, as the Company’s sales agent. In June 2020, the 2019 Sales Agreement was amended to reduce the aggregate offering amount under the 2019 Sales Agreement from $75,000 of shares to $30,000 of shares. On August 11, 2020, the 2019 Sales Agreement was terminated by the execution by the Company and the Agent of a new sales agreement, which was subsequently amended on October 21, 2020 (as amended,the "2020 Sales Agreement"). Under the 2020 Sales Agreement the Company may sell, from time to time, at its option, up to an aggregate of $62,500 of shares of the Company's common stock, $0.001 par value per share (the "Shares"), through the Agent, as the Company's sales agent. Any Shares to be offered and sold under the 2020 Sales Agreement will be issued and sold (i) by methods deemed to be an "at the market offering" ("ATM") as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended or in negotiated transactions, if authorized by the Company and (ii) pursuant to, and only upon the effectiveness of, a registration statement on Form S-3 filed by the Company with the Securities and Exchange Commission on August 11, 2020 for an offering of up to $350,000 of various securities, including shares of the Company's common stock, preferred stock, debt securities, warrants and/or units for sale to the public in one or more public offerings. Subject to the terms of the 2020 Sales Agreement, the Agent will use reasonable efforts to sell the Shares from time to time, based upon the Company's instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company cannot provide any assurances that it will issue any Shares pursuant to the 2020 Sales Agreement. The Company will pay the Agent a commission of up to 3.0% of the gross proceeds from the sale of the Shares, if any. The Company has also agreed to provide the Agent with customary indemnification rights. During the year ended March 31, 2020, the Company issued and sold 287,559 shares of common stock under the 2019 Sales Agreement, for gross proceeds of $4,568 less offering fees of $137 for net proceeds of $4,431 under the ATM. The Company has not issued and sold any shares under the 2020 Sales Agreement as of December 31, 2020. Equity offerings In November 2019, the Company entered into an underwriting agreement (the “November 2019 Underwriting Agreement”) with J.P. Morgan Securities LLC and SVB Leerink LLC, as representatives of the several underwriters named therein (the “November 2019 Underwriters”), relating to the issuance and sale of an aggregate of (a) 3,678,031 shares of the Company’s common stock (the “November 2019 Shares”), and (b) pre-funded warrants to purchase 2,200,000 shares of the Company’s common stock (the “November 2019 Pre-Funded Warrants”) to the November 2019 Underwriters (the “November 2019 Offering”). The November 2019 Shares were sold at the public offering price of $13.61 per share. The November 2019 Pre-Funded Warrants were sold at a public offering price of $13.6099 per November 2019 Pre-Funded Warrant, which represented the per share public offering price for the November 2019 Shares less a $0.0001 per share exercise price for each such November 2019 Pre-Funded Warrant. In December 2019, the November 2019 Underwriters partially exercised their purchase option pursuant to the November 2019 Underwriting Agreement, and the Company issued and sold an additional 838,530 shares of its common stock. The Company received aggregate net proceeds of approximately $85,598 in the November 2019 Offering, after deducting underwriting discounts, commissions and other offering expenses payable by the Company of approximately $5,814. Funds affiliated with Redmile Group, LLC purchased all of the November 2019 Pre-Funded Warrants. The November 2019 Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of November 2019 Pre-Funded Warrants may not exercise the November 2019 Pre-Funded Warrants if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. In June 2020, the Company entered into a separate underwriting agreement (the “June 2020 Underwriting Agreement”) with J.P. Morgan Securities LLC and SVB Leerink LLC, as representatives of the several underwriters named therein (the “June 2020 Underwriters”), relating to the issuance and sale of an aggregate of (a) 2,826,088 shares of the Company’s common stock (the “June 2020 Shares”), and (b) pre-funded warrants to purchase 1,521,738 shares of the Company’s common stock (the “June 2020 Pre-Funded Warrants”) to the June 2020 Underwriters. The June 2020 Shares were sold at the public offering price of $23.00 per share. The June 2020 Pre-Funded Warrants were sold at a public offering price of $22.9999 per June 2020 Pre-Funded Warrant, which represented the per share public offering price for the June 2020 Shares less a $0.0001 per share exercise price for each such June 2020 Pre-Funded Warrant. The June 2020 Underwriters fully exercised their purchase option pursuant to the June 2020 Underwriting Agreement, and the Company issued and sold an additional 652,173 shares of its common stock. The Company received aggregate net proceeds of approximately $107,782 after deducting underwriting discounts, commissions and other offering expenses payable by the Company of approximately $7,217. Funds affiliated with Redmile Group, LLC and funds affiliated with a second institutional investor purchased all of the June 2020 Pre-Funded Warrants. The June 2020 Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of June 2020 Pre-Funded Warrants may not exercise the June 2020 Pre-Funded Warrants if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. A holder of June 2020 Pre-Funded Warrants may increase or decrease this percentage up to 19.99% by providing at least 61 days’ prior notice to the Company. In October 2020, pursuant to an underwriting agreement with J.P. Morgan Securities LLC and SVB Leerink LLC, as representatives of the several underwriters named therein, the Company issued and sold to the underwriters (a) 5,625,000 shares of the Company's common stock, inclusive of the underwriters 30-day option to purchase up to an additional 937,500 shares of the Company's common stock, and (b) pre-funded warrants to purchase 1,562,500 shares of the Company's common stock (the "October 2020 Pre-Funded Warrants"). The shares of the Company's common stock were sold to the underwriters at the public offering price of $40.00 per share and the pre-funded warrants were sold at a public offering price of $39.99 per October 2020 Pre-Funded Warrant, which represented the per share public offering price for the Company's common stock less a $0.0001 per share exercise price for each such pre-funded warrant. The Company received aggregate net proceeds of approximately $269,975 after deducting underwriting discounts, commissions and other offering expenses payable by the Company of approximately $17,525. Funds affiliated with Redmile Group, LLC and funds affiliated with a second institutional investor purchased all of the October 2020 Pre-Funded Warrants. The October 2020 Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of October 2020 Pre-Funded Warrants may not exercise the October 2020 Pre-Funded Warrants if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company's common stock outstanding immediately after giving effect to such exercise. A holder of October 2020 Pre-Funded Warrants may increase or decrease this percentage up to 19.99% by providing at least 61 days' prior notice to the Company. Other than as set forth in Note 10 to these consolidated financial statements, including in the calculation of basic and diluted net loss per share attributable to common stockholders, the 5,284,238 shares of the Company’s common stock into which the November 2019 Pre-Funded Warrants, the June 2020 Pre-Funded Warrants and October 2020 Pre-Funded Warrants are exercisable are not included in the number of issued and outstanding shares of the Company’s common stock set forth herein. As of December 31, 2020, none of the November 2019 Pre-Funded Warrants, the June 2020 Pre-Funded Warrants, or the October 2020 Pre-Funded Warrants had been exercised.

Stock-based compensation

Stock-based compensation	9 Months Ended
	Dec. 31, 2020
Stock-based compensation
Stock-based compensation	9. Stock‑based compensation 2015 Enterprise Management Incentive Share Option Plan The 2015 Enterprise Management Incentive Share Option Plan of Replimune UK (the “2015 Plan”) provided for Replimune UK to grant incentive stock options, non‑statutory stock options, stock awards, stock units, stock appreciation rights and other stock‑ based awards. Incentive stock options are granted only to the Company’s employees, including officers and directors who are also employees. Non‑statutory stock options are granted to employees, members of the board of directors, outside advisors and consultants of the Company. 2017 Equity Compensation Plan In July 2017, in conjunction with the Reorganization, the 2015 Plan was terminated, and all awards were cancelled with replacement awards issued under the 2017 Equity Compensation Plan (the “2017 Plan”). Subsequent to the Reorganization, no additional grants will be made under the 2015 Plan and any outstanding awards under the 2015 Plan will continue with their original terms. The Company concluded that the cancellation of the 2015 Plan and issuance of replacement awards under the 2017 Plan was a modification with no change in the material rights and preferences and therefore no recorded change in the fair value of each respective award. The Company’s 2017 Plan provides for the Company to grant incentive stock options or non‑statutory stock options, stock awards, stock units, stock appreciation rights and other stock‑ based awards. Incentive stock options may be granted only to the Company’s employees, including officers and directors who are also employees. Restricted stock awards and non‑statutory stock options may be granted to employees, officers, members of the board of directors, advisors and consultants of the Company. The maximum number of common shares that may be issued under the 2017 Plan was 2,659,885, of which none remained available for future grants as of December 31, 2020. Shares with respect to which awards have expired, terminated, surrendered or cancelled under the 2017 Plan without having been fully exercised will be available for future awards under the 2017 Plan. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards. 2018 Omnibus Incentive Compensation Plan On July 9, 2018, the Company’s board of directors adopted, and the Company’s stockholders approved the 2018 Omnibus Incentive Compensation Plan (the “2018 Plan”), which became effective immediately prior to the effectiveness of the registration statement for the Company’s initial public offering. The 2018 Plan provides for the issuance of incentive stock options, non-qualified stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. The number of shares initially reserved for issuance under the 2018 Plan is 3,617,968 shares. If any options or stock appreciation rights, including outstanding options and stock appreciation rights granted under the 2017 Plan (up to 2,520,247 shares), terminate, expire, or are canceled, forfeited, exchanged, or surrendered without having been exercised, or if any stock awards, stock units or other stock-based awards, including outstanding awards granted under the 2017 Plan, are forfeited, terminated, or otherwise not paid in full in shares of common stock, the shares of the Company’s common stock subject to such grants will be available for purposes of our 2018 Plan. On April 1, 2020, the number of shares reserved for issuance under the 2018 Plan automatically increased by 1,466,749 shares pursuant to the terms of the 2018 Plan. On April 1, 2019, the number of shares reserved for issuance under the 2018 Plan automatically increased by 1,266,278 shares pursuant to the terms of the 2018 Plan. As of December 31, 2020, 1,613,894 shares remained available for future grants under the 2018 Plan. The 2015 Plan, the 2017 Plan and the 2018 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. However, the board of directors shall administer and approve all grants made to non-employee directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, except that the exercise price per share of incentive stock options may not be less than 100% of the fair market value of the common stock on the date of grant (or 110% of fair value in the case of an award granted to employees who hold more than 10% of the total combined voting power of all classes of stock at the time of grant) and the term of stock options may not be greater than five years for an incentive stock option granted to a 10% stockholder and greater than ten years for all other options granted. Stock options awarded under both plans expire ten years after the grant date, unless the board of directors sets a shorter term. Vesting periods for both plans are determined at the discretion of the board of directors. Incentive stock options granted to employees and non-statutory options granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. Employee Stock Purchase Plan On July 9, 2018, the Company’s board of directors adopted and the Company’s stockholders approved the Employee Stock Purchase Plan (the “ESPP”), which became effective immediately prior to the effectiveness of the registration statement for the Company’s IPO. The total shares of common stock initially reserved for issuance under the ESPP is limited to 348,612 shares. In addition, as of the first trading day of each fiscal year during the term of the ESPP (excluding any extensions), an additional number of shares of the Company’s common stock equal to 1% of the total number of shares outstanding on the last trading day in the immediately preceding fiscal year or 697,224 shares, whichever is less (or such lesser amount as determined by the Company’s board of directors) will be added to the number of shares authorized under the ESPP. In accordance, on April 1, 2020 and 2019, the number of shares reserved for issuance under the ESPP automatically increased by 366,687 and 316,569 shares respectively, for a total of 1,031,868 shares reserved for the ESPP. If the total number of shares of common stock to be purchased pursuant to outstanding purchase rights on any particular date exceed the number of shares then available for issuance under the ESPP, then the plan administrator will allocate the available shares pro-rata and refund any excess payroll deductions or other contributions to participants. The Company's ESPP is not currently active. Stock option valuation The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company lacks company- specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The following table presents, on a weighted-average basis, the assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors: Three Months Ended Nine Months Ended December 31, December 31, 2020 2019 2020 2019 Risk-free interest rate 0.31 % 1.68 % 1.01 % 2.17 % Expected term (in years) 6.0 Expected volatility 76.3 % 69.7 % 74.8 % 71.0 % Expected dividend yield % % % % Stock options The following table summarizes the Company’s stock option activity: Weighted Weighted Average Number of Average Contractual Term Aggregate Shares Exercise Price (Years) Intrinsic Value Outstanding as of March 31, 2020 4,964,381 $ 9.78 8.02 $ 15,345 Granted 2,284,004 9.37 Exercised (612,671) 6.79 Cancelled (309,137) Outstanding as of December 31, 2020 6,326,577 $ 167,873 Options exercisable as of March 31, 2020 2,117,721 $ $ 11,733 Options exercisable as of December 31, 2020 2,617,429 $ $ 79,395 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The weighted average grant-date fair value per share of stock options granted during the nine months ended December 31, 2020 and 2019 was $10.06 and $9.63, respectively. The total fair value of options vested during the three months and nine months ended December 31, 2020 was $2,069 and $8,330, respectively. The total fair value of options vested during the three months and nine months ended December 31, 2019 was $1,063 and $4,480, respectively. Stock‑based compensation expense Stock‑based compensation expense was classified in the consolidated statements of operations as follows: Three Months Ended Nine Months Ended December 31, December 31, 2020 2019 2020 2019 Research and development $ 1,454 $ 1,318 $ 3,750 $ 2,974 General and administrative 1,595 1,026 4,568 2,961 $ 3,049 $ 2,344 $ 8,318 $ 5,935 As of December 31, 2020, total unrecognized compensation cost related to the unvested stock‑based awards was $31,002, which is expected to be recognized over a weighted average period of 2.95 years.

Net loss per share

Net loss per share	9 Months Ended
	Dec. 31, 2020
Net loss per share
Net loss per share	10. Net loss per share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended December 31, Nine Months Ended December 31, 2020 2019 2020 2019 Numerator: Net loss attributable to common stockholders $ (21,783) $ (16,189) $ (59,371) $ (36,836) Denominator: Weighted average common shares outstanding, basic and diluted 49,382,213 34,877,944 44,436,680 32,742,148 Net loss per share attributable to common stockholders, basic and diluted $ (0.44) $ (0.46) $ (1.34) $ (1.13) The November 2019 Pre-Funded Warrants, the June 2020 Pre-Funded Warrants and October 2020 Pre-Funded Warrants are included as outstanding common stock in the calculation of basic and diluted net loss per share attributable to common stockholders. The Company’s potentially dilutive securities, which include stock options and warrants to purchase shares of series seed preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti‑dilutive effect: Three and Nine Months Ended December 31, 2020 2019 Options to purchase common stock 6,326,577 4,916,402 Warrants to purchase convertible preferred stock (as converted to common stock) 497,344 497,344 6,823,921 5,413,746

Significant agreements

Significant agreements	9 Months Ended
	Dec. 31, 2020
Significant agreements
Significant agreements	11. Significant agreements Agreement with Bristol-Myers Squibb Company In February 2018, the Company entered into an agreement with Bristol-Myers Squibb Company (“BMS”). Pursuant to the agreement, BMS will provide to the Company, at no cost, a compound for use in the Company’s ongoing clinical trial of RP1. Under the agreement, the Company will sponsor, fund and conduct the clinical trial in accordance with an agreed-upon protocol. BMS granted the Company a non-exclusive, non-transferrable, royalty-free license (with a right to sublicense) under its intellectual property to its compound in the clinical trial and agreed to supply its compound, at no cost to the Company, for use in the clinical trial. In January 2020, this agreement was expanded to cover an additional cohort of 125 patients with anti-PD-1 failed melanoma. Unless earlier terminated, the agreement will remain in effect until (i) the completion of the clinical trial, (ii) all related clinical trial data have been delivered to both parties and (iii) the completion of any statistical analyses and bioanalyses contemplated by the clinical trial protocol or any analysis otherwise agreed upon by the parties. The agreement may be terminated by either party (i) in the event of an uncured material breach by the other party, (ii) in the event the other party is insolvent or in bankruptcy proceedings or (iii) for safety reasons. Upon termination, the licenses granted to the Company to use BMS’s compound in the clinical trial will terminate. In April 2019, the Company entered into a separate agreement with BMS on terms similar to the terms set forth in the agreement described above, pursuant to which BMS will provide to the Company, at no cost, nivolumab for use in the Company's Phase 1 clinical trial of RP2 in combination with nivolumab. As of December 31, 2020, the Company had not incurred any costs and does not expect to incur future costs in connection with this agreement. Agreement with Regeneron Pharmaceuticals, Inc . In May 2018, the Company entered into an agreement with Regeneron Pharmaceuticals, Inc. (“Regeneron”). The Company and Regeneron are each independently developing compounds for the treatment of certain tumor types. Pursuant to the agreement, the Company and Regeneron will undertake one or more clinical trials using a combination of the compounds being developed by each entity. Under the agreement, each study will be conducted under terms set out in a separately agreed upon study plan that will identify the name of the sponsor and which party will manage the particular clinical trial, and include the protocol, the budget and a schedule of clinical obligations. In June 2018, under the terms of the agreement between the Company and Regeneron, the parties agreed to the first study plan. The Company and Regeneron have agreed to the protocol, budget, sample testing and clinical obligations schedule under the study plan. Development and supply costs associated with the study plan will be split equally between the Company and Regeneron. Pursuant to the terms of the agreement, each party granted the other party a non-exclusive license under its respective intellectual property and agreed to contribute the necessary resources needed to fulfill its respective obligations, in each case, under the terms of the agreed-upon or to-be agreed upon study plans. Development costs of a particular clinical trial will be split equally between the Company and Regeneron in accordance with the agreed upon study plan. The agreement may be terminated by either party if (i) there is no active study plan for which a final study report has not been completed, (ii) the parties have not entered into a study plan for an additional clinical trial within a period of time after the delivery of the most recent final study report or (iii) in the event of a material breach. The Company will account for costs incurred as part of the study, including costs to supply compounds for use in the study, as research and development expenses within the consolidated statement of operations. The Company will recognize any amounts received from Regeneron in connection with this agreement as an offset to research and development expense within the consolidated statement of operations. Under the terms of the agreement, on a quarterly basis the Company and Regeneron true-up costs of the study and make corresponding payments to the party that incurred the majority of the costs. During the three and nine months ended December 31, 2020 or 2019, the Company did not make any payments under the terms of the agreement from Regeneron. During the three and nine months ended December 31, 2020, the Company received payments under the terms of the agreement from Regeneron of $1,453 and $3,857, respectively. During the three and nine months ended December 31, 2019, the Company received payments under the terms of the agreement from Regeneron of $760 and $2008, respectively. As of December 31, 2020 and March 31, 2020, the Company recorded $1,195 and $971 of receivables from Regeneron in connection with this agreement in prepaid expenses and other current assets in the consolidated balance sheet, respectively.

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Dec. 31, 2020
Commitments and contingencies
Commitments and contingencies	12. Commitments and contingencies Leases In April 2016, the Company entered into a lease agreement for office and laboratory space in Abingdon, England. On June 29, 2020 the Company modified the lease terms to extend the expiration date to April 3, 2031 and the lease modification was not accounted for as a separate contract. As part of the lease modification, the lease liability was remeasured in accordance with the updated terms of the contract and the associated lease liability and right-of-use asset was increased by $1,580. The Company has the right to terminate the lease as of April 4, 2026 upon at least twelve months’ prior written notice. Monthly lease payments are inclusive of base rent, ancillary charges, non‑rent shared tenant occupancy costs and the respective value added tax to be paid. Monthly lease payments include base rent of approximately $29 through June 23, 2020, $14 from June 24, 2020 through December 24, 2020, and $29 thereafter. Monthly base rent is subject to increase after April 2021 in proportion to the Retail Price Index or market rates. The lease is classified as an operating lease. In June 2018, the Company entered into an agreement to lease approximately 63,000 square feet of office, manufacturing and laboratory space in Framingham, Massachusetts. Pursuant to the lease agreement, the lease term commenced in December 2018, subject to the landlord completing certain agreed upon landlord improvements. The rent commencement date started in August 2019. The initial lease term is ten years from the rent commencement date and includes two optional five-year extensions. Annual lease payments during the first year were $2,373 with increases of 3.0% each year thereafter until the expiration of the lease. Construction was completed associated with approximately 10,500 square feet of the leased space in Framingham, Massachusetts and the Company occupied the building as office space beginning August 1, 2019. The Company recorded a right-of-use asset and lease liability associated with the occupied space as of August 1, 2019. The Company recorded $2,368 in related construction costs to the right-of-use asset upon the lease commencement date which were reclassified from prepaid rent. The Company occupied the remainder of the facility, approximately 52,500 square feet used as laboratory space, on October 22, 2019. The Company recorded a right-of-use asset and lease liability associated with the remaining space as of October 22, 2019. The Company recorded $18,164 in related construction costs and $261 in rent payments made prior to the lease commencement date to the right-of-use asset upon the lease commencement date which were reclassified from prepaid rent. The lease is classified as a financing lease. In June 2019, the Company entered into an agreement to lease approximately 18,700 square feet of office space in Woburn, Massachusetts. Pursuant to the lease agreement, the lease term commenced in August 2019. The rent commenced in September 2019. The initial lease term is ten years from the rent commencement date and includes an optional five-year extension. Annual lease payments during the first year are $488 with increases of approximately 1.6% each year. The Company recorded a right-of-use asset and a lease liability of $4,363 upon the commencement date of the lease and the lease is classified as an operating lease. The Company determines if an arrangement is a lease at inception. Operating leases are included in our balance sheet as right-to-use—operating leases, operating lease liabilities, current and operating lease liabilities, non-current. Finance leases are included in the balance sheet as right-to-use asset—finance lease finance lease liabilities, current, and finance lease liabilities, non-current. Certain of the Company’s lease agreements contain renewal options; however, the Company does not recognize right-of-use assets or lease liabilities for renewal periods unless it is determined that the Company is reasonably certain of renewing the lease at inception or when a triggering event occurs. As the Company’s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. Some of the Company’s lease agreements contain rent escalation clauses (including index-based escalations). The Company recognizes the minimum rental expense on a straight-line basis based on the fixed components of a lease arrangement. The Company amortizes this expense over the term of the lease beginning with the date of initial possession, which is the date the Company can enter the leased space and begin to make improvements in preparation for its intended use. Variable lease components represent amounts that are not fixed in nature and are not tied to an index or rate, and are recognized as incurred. Three Months Ended Nine Months Ended December 31, December 31, 2020 2019 2020 2019 Lease cost Finance lease costs: Amortization of right-to-use asset $ 607 $ 607 $ 1,821 $ 666 Interest on lease liabilities 560 591 1,683 652 Operating lease costs 239 262 705 633 Total lease cost $ 1,406 $ 1,460 $ 4,209 $ 1,951 Finance lease costs of $90 and $90 are recognized in general and administrative expenses for the three months ended December 31, 2020 and 2019, respectively, and $268 and $149 for the nine months ended September 30, 2020 and 2019, respectively. Finance lease costs of $518 and $517 are recognized in research and development expenses for the three months ended December 31, 2020 and 2019, respectively, and $1,553 and $517 for the nine months ended December 31, 2020 and 2019, respectively. Operating leases costs are recognized in general and administrative expenses for the three and nine months ended December 31, 2020 and 2019. The following table summarizes the maturity of the Company’s lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating and financing lease liabilities recognized on our balance sheet as of September 30, 2020: December 31, 2020 Operating leases Financing lease Total 2021 (remaining three months) $ 240 $ 611 $ 851 2022 967 2,487 3,454 2023 976 2,562 3,538 2024 986 2,639 3,625 2025 995 2,718 3,713 Thereafter 5,054 43,704 48,758 Total lease payments 9,218 54,721 63,939 Less: interest 3,083 27,437 30,520 Total lease liabilities $ 6,135 $ 27,284 $ 33,419 The following table provides lease disclosure as of December 31, 2020 and March 31, 2020: December 31, 2020 March 31, 2020 Leases Right-to-use operating lease asset $ 5,839 $ 4,425 Right-to-use finance lease asset 45,129 46,925 Total lease assets $ 50,968 $ 51,350 Operating lease liabilities, current $ 965 $ 873 Finance lease liabilities, current 2,469 2,411 Operating lease liabilities, non-current 5,170 3,737 Finance lease liabilities, non-current 24,815 24,967 Total lease liabilities $ 33,419 $ 31,988 The following table provides lease disclosure for the nine months ended December 31, 2020 and 2019: Nine Months Ended December 31, 2020 2019 Other information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 582 $ 516 Operating cash flows from finance leases $ 1,682 $ 623 Financing cash flows from finance leases $ 92 $ 22 Right-to-use asset obtained in exchange for new operating lease liabilities $ 1,580 $ 5,152 Weighted-average remaining lease term - operating leases 9.1 years 8.6 years Weighted-average remaining lease term - financing leases 18.6 years 19.6 years Weighted-average discount rate - operating leases 9.8 % 7 % Weighted-average discount rate - financing leases 8.3 % 8 % The variable lease costs and short-term lease costs were insignificant for three and nine months ended December 31, 2020 and 2019. Manufacturing commitments The Company has entered into an agreement with a contract manufacturing organization to provide clinical trial products. As of December 31, 2020 and March 31, 2020, the Company had committed to minimum payments under these arrangements totaling $1,622 and $3,569, respectively, through March 31, 2021. Indemnification agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its executive management team and its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and therefore it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2020 or March 31, 2020. Legal proceedings The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities.

Geographic information

Geographic information	9 Months Ended
	Dec. 31, 2020
Geographic information
Geographic information	13. Geographic information The Company operates in two geographic regions: the United States (Massachusetts) and the United Kingdom (Oxfordshire). Information about the Company’s long-lived assets held in different geographic regions is presented in the tables below: December 31, 2020 March 31, 2020 United States $ 6,564 $ 6,357 United Kingdom 602 503 $ 7,166 $ 6,860

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	9 Months Ended
	Dec. 31, 2020
Summary of significant accounting policies
Principles of consolidation	Principles of consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Replimune UK, Replimune US, Replimune Securities Corporation and Replimune (Ireland) Limited after elimination of all intercompany accounts and transactions.
Use of estimates	Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock‑based awards. The Company bases its estimates on historical experience, known trends and other market‑specific or other relevant factors that it believes to be reasonable under the circumstances. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including, expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.
Unaudited interim financial information	Unaudited interim financial information The accompanying consolidated balance sheet as of December 31, 2020, the consolidated statements of operations, of comprehensive loss and of stockholders’ equity for the three and nine months ended December 31, 2020 and 2019 and the consolidated statements of cash flows for the nine months ended December 31, 2020 and 2019 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of December 31, 2020 and the results of its operations for the three and nine months ended December 31, 2020 and 2019 and its cash flows for the nine months ended December 31, 2020 and 2019. The financial data and other information disclosed in these consolidated notes related to the three and nine months ended December 31, 2020 and 2019 are unaudited. The results for the three and nine months ended December 31, 2020 are not necessarily indicative of results to be expected for the year ending March 31, 2021, any other interim periods or any future year or period. The financial information included herein should be read in conjunction with the financial statements and notes in the Company's Annual Report on Form 10-K for the year ended March 31, 2020. During the three and nine months ended December 31, 2020, there have been no changes to the Company’s significant accounting policies as described in the Company's Annual Report on Form 10-K for the year ended March 31, 2020 which was filed with the Securities and Exchange Commission on June 3, 2020, except as described below.
Recently adopted accounting pronouncements and Recently issued accounting pronouncements	Recently adopted accounting pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). The amendments in this ASU require certain existing disclosure requirements in Topic 820 to be modified or removed, and certain new disclosure requirements to be added to the Topic. In addition, this ASU allows entities to exercise more discretion when considering fair value measurement disclosures. The Company adopted ASU 2018-13 on April 1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company's consolidated financial statements. In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”), which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in Topic 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. The standard adds unit-of-account guidance in Topic 808 to align with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606, and requires that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The standard is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, including adoption in any interim period for public business entities for periods in which financial statements have not been issued. Amendments in the standard should be applied retrospectively to the date of initial application of Topic 606, but entities may elect to apply the amendments in this Update retrospectively either to all contracts or only to contracts that are not completed at the date of initial application of Topic 606, and should disclose the election. An entity may also elect to apply the practical expedient for contract modifications that is permitted for entities using the modified retrospective transition method in Topic 606. The Company adopted ASU 2018-18 on April 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company's consolidated financial statements. Recently issued accounting pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments- Credit Losses (Topic 326). The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments – Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326), which provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. The standard is effective for fiscal years and interim periods beginning after December 15, 2022. Early adoption is permitted for all periods beginning after December 15, 2018. The adoption of ASU 2016-13 is not expected to have a material impact on the Company's consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12 ), as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The standard is effective for fiscal years and interim periods beginning after December 15, 2020. The Company is currently evaluating the impact of this new guidance on its financial statements and related disclosures but does not expect the adoption of ASU 2019-12 to have a material impact on the Company's consolidated financial statements.

Fair value of financial asset_2

Fair value of financial assets and liabilities (Tables)	9 Months Ended
	Dec. 31, 2020
Fair value of financial assets and liabilities
Schedule of company's financial assets and liabilities measured at fair value on a recurring basis	Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets Money market funds $ — $ 276,076 $ — $ 276,076 US Government Agency bonds — 63,295 — 63,295 US Treasury bonds — 105,502 — 105,502 $ — $ 444,873 $ — $ 444,873 Fair Value Measurements as of March 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets Money market funds $ — $ 36,712 $ — $ 36,712 Commercial paper — 21,884 — 21,884 US Treasury bonds — 35,810 — 35,810 US Government Agency bonds — 15,295 — 15,295 Corporate debt securities — 36,066 — 36,066 $ — $ 145,767 $ — $ 145,767

Short-term investments (Tables)

Short-term investments (Tables)	9 Months Ended
	Dec. 31, 2020
Short-term investments
Schedule of short-term investments	December 31, 2020 Gross Gross Amortized unrealized unrealized cost gains losses Fair value US Government agency bonds $ 63,284 $ 11 $ — $ 63,295 US Treasury bonds 105,487 17 (2) 105,502 $ 168,771 $ 28 $ (2) $ 168,797 March 31, 2020 Gross Gross Amortized unrealized unrealized cost gains losses Fair value Commercial paper $ 21,818 $ 66 $ — $ 21,884 US Government agency bonds 15,217 78 — 15,295 US Treasury bonds 35,590 220 — 35,810 Corporate debt securities 36,107 24 (65) 36,066 $ 108,732 $ 388 $ (65) $ 109,055

Property, plant and equipment_2

Property, plant and equipment, net (Tables)	9 Months Ended
	Dec. 31, 2020
Property, plant and equipment, net
Schedule of property, plant and equipment, net	December 31, March 31, 2020 2020 Construction in progress $ 1,363 $ 1,217 Plant and laboratory equipment 4,784 3,669 Leasehold improvements 785 532 Computer equipment 1,667 1,658 Office equipment 721 721 9,320 7,797 Less: Accumulated depreciation and amortization (2,154) (937) $ 7,166 $ 6,860

Accrued expenses and other cu_2

Accrued expenses and other current liabilities (Tables)	9 Months Ended
	Dec. 31, 2020
Accrued expenses and other current liabilities
Schedule of accrued expenses and other current liabilities	December 31, March 31, 2020 2020 Accrued research and development costs $ 3,714 $ 2,009 Accrued compensation and benefits costs 2,638 2,065 Accrued professional fees 363 779 Other 519 303 $ 7,234 $ 5,156

Long-term debt (Tables)

Long-term debt (Tables)	9 Months Ended
	Dec. 31, 2020
Long-term debt
Schedule of long-term debt	December 31, March 31, 2020 2020 Principal amount of long-term debt $ — $ 10,000 Unamortized debt discount — (199) Long-term debt, net of discount $ — $ 9,801

Stock-based compensation (Table

Stock-based compensation (Tables)	9 Months Ended
	Dec. 31, 2020
Stock-based Compensation
Summary of stock option activity	Weighted Weighted Average Number of Average Contractual Term Aggregate Shares Exercise Price (Years) Intrinsic Value Outstanding as of March 31, 2020 4,964,381 $ 9.78 8.02 $ 15,345 Granted 2,284,004 9.37 Exercised (612,671) 6.79 Cancelled (309,137) Outstanding as of December 31, 2020 6,326,577 $ 167,873 Options exercisable as of March 31, 2020 2,117,721 $ $ 11,733 Options exercisable as of December 31, 2020 2,617,429 $ $ 79,395
Schedule of stock-based compensation expense	Three Months Ended Nine Months Ended December 31, December 31, 2020 2019 2020 2019 Research and development $ 1,454 $ 1,318 $ 3,750 $ 2,974 General and administrative 1,595 1,026 4,568 2,961 $ 3,049 $ 2,344 $ 8,318 $ 5,935
Employees stock options
Stock-based Compensation
Schedule of assumptions used to determine the grant-date fair value of stock options granted	Three Months Ended Nine Months Ended December 31, December 31, 2020 2019 2020 2019 Risk-free interest rate 0.31 % 1.68 % 1.01 % 2.17 % Expected term (in years) 6.0 Expected volatility 76.3 % 69.7 % 74.8 % 71.0 % Expected dividend yield % % % %

Net loss per share (Tables)

Net loss per share (Tables)	9 Months Ended
	Dec. 31, 2020
Net loss per share
Schedule of calculation of basic and diluted net loss per share attributable to common stockholders	Three Months Ended December 31, Nine Months Ended December 31, 2020 2019 2020 2019 Numerator: Net loss attributable to common stockholders $ (21,783) $ (16,189) $ (59,371) $ (36,836) Denominator: Weighted average common shares outstanding, basic and diluted 49,382,213 34,877,944 44,436,680 32,742,148 Net loss per share attributable to common stockholders, basic and diluted $ (0.44) $ (0.46) $ (1.34) $ (1.13)
Schedule of anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders	Three and Nine Months Ended December 31, 2020 2019 Options to purchase common stock 6,326,577 4,916,402 Warrants to purchase convertible preferred stock (as converted to common stock) 497,344 497,344 6,823,921 5,413,746

Commitments and contingencies (

Commitments and contingencies (Tables)	9 Months Ended
	Dec. 31, 2020
Commitments and contingencies
Schedule of variable lease components	Three Months Ended Nine Months Ended December 31, December 31, 2020 2019 2020 2019 Lease cost Finance lease costs: Amortization of right-to-use asset $ 607 $ 607 $ 1,821 $ 666 Interest on lease liabilities 560 591 1,683 652 Operating lease costs 239 262 705 633 Total lease cost $ 1,406 $ 1,460 $ 4,209 $ 1,951
Summary of the maturity of company's lease liabilities	December 31, 2020 Operating leases Financing lease Total 2021 (remaining three months) $ 240 $ 611 $ 851 2022 967 2,487 3,454 2023 976 2,562 3,538 2024 986 2,639 3,625 2025 995 2,718 3,713 Thereafter 5,054 43,704 48,758 Total lease payments 9,218 54,721 63,939 Less: interest 3,083 27,437 30,520 Total lease liabilities $ 6,135 $ 27,284 $ 33,419
Schedule of additional information related to leases	The following table provides lease disclosure as of December 31, 2020 and March 31, 2020: December 31, 2020 March 31, 2020 Leases Right-to-use operating lease asset $ 5,839 $ 4,425 Right-to-use finance lease asset 45,129 46,925 Total lease assets $ 50,968 $ 51,350 Operating lease liabilities, current $ 965 $ 873 Finance lease liabilities, current 2,469 2,411 Operating lease liabilities, non-current 5,170 3,737 Finance lease liabilities, non-current 24,815 24,967 Total lease liabilities $ 33,419 $ 31,988 The following table provides lease disclosure for the nine months ended December 31, 2020 and 2019: Nine Months Ended December 31, 2020 2019 Other information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 582 $ 516 Operating cash flows from finance leases $ 1,682 $ 623 Financing cash flows from finance leases $ 92 $ 22 Right-to-use asset obtained in exchange for new operating lease liabilities $ 1,580 $ 5,152 Weighted-average remaining lease term - operating leases 9.1 years 8.6 years Weighted-average remaining lease term - financing leases 18.6 years 19.6 years Weighted-average discount rate - operating leases 9.8 % 7 % Weighted-average discount rate - financing leases 8.3 % 8 %

Geographic information (Tables)

Geographic information (Tables)	9 Months Ended
	Dec. 31, 2020
Geographic information
Summary of company's long-lived assets held in different geographic regions	December 31, 2020 March 31, 2020 United States $ 6,564 $ 6,357 United Kingdom 602 503 $ 7,166 $ 6,860

Nature of the business (Details

Nature of the business (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Nature of the business
Net loss	$ (21,783)	$ (20,095)	$ (17,493)	$ (16,189)	$ (11,139)	$ (9,508)	$ (59,371)	$ (36,836)
Accumulated deficit	$ (171,669)						$ (171,669)		$ (112,298)

Fair value of financial asset_3

Fair value of financial assets and liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Fair value of financial assets and liabilities
Transfer from Leve 1 to Level 2, assets	$ 0	$ 0	$ 0	$ 0
Transfer from Leve 2 to Level 1, assets	0	0	0	0
Transfers into Level 3, assets	0	0	0	0
Transfer out of Level 3, assets	0	0	0	0
Transfer from Leve 1 to Level 2, liabilities	0	0	0	0
Transfer from Leve 2 to Level 1, liabilities	0	0	0	0
Transfers into Level 3, liabilities	0	0	0	0
Transfer out of Level 3, liabilities	0	$ 0	0	$ 0
Recurring
Fair value of financial assets and liabilities
Assets fair value	444,873		444,873		$ 145,767
Level 2 | Recurring
Fair value of financial assets and liabilities
Assets fair value	444,873		444,873		145,767
Money market funds | Recurring
Fair value of financial assets and liabilities
Assets fair value	276,076		276,076		36,712
Money market funds | Level 2 | Recurring
Fair value of financial assets and liabilities
Assets fair value	276,076		276,076		36,712
Commercial paper | Recurring
Fair value of financial assets and liabilities
Assets fair value					21,884
Commercial paper | Level 2 | Recurring
Fair value of financial assets and liabilities
Assets fair value					21,884
US Treasury bonds | Recurring
Fair value of financial assets and liabilities
Assets fair value	105,502		105,502		35,810
US Treasury bonds | Level 2 | Recurring
Fair value of financial assets and liabilities
Assets fair value	105,502		105,502		35,810
US Government Agency bonds | Recurring
Fair value of financial assets and liabilities
Assets fair value	63,295		63,295		15,295
US Government Agency bonds | Level 2 | Recurring
Fair value of financial assets and liabilities
Assets fair value	$ 63,295		$ 63,295		15,295
Corporate debt securities | Recurring
Fair value of financial assets and liabilities
Assets fair value					36,066
Corporate debt securities | Level 2 | Recurring
Fair value of financial assets and liabilities
Assets fair value					$ 36,066

Short-term investments (Details

Short-term investments (Details) - Short-term investments - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Mar. 31, 2020
Short-term investments
Amortized cost	$ 168,771	$ 108,732
Gross unrealized gains	28	388
Gross unrealized losses	(2)	(65)
Fair value	168,797	109,055
Commercial paper
Short-term investments
Amortized cost		21,818
Gross unrealized gains		66
Fair value		21,884
US Government Agency bonds
Short-term investments
Amortized cost	63,284	15,217
Gross unrealized gains	11	78
Fair value	63,295	15,295
US Treasury bonds
Short-term investments
Amortized cost	105,487	35,590
Gross unrealized gains	17	220
Gross unrealized losses	(2)
Fair value	$ 105,502	35,810
Corporate debt securities
Short-term investments
Amortized cost		36,107
Gross unrealized gains		24
Gross unrealized losses		(65)
Fair value		$ 36,066

Property, plant and equipment_3

Property, plant and equipment, net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Property, plant and equipment, net
Property, plant and equipment , gross	$ 9,320		$ 9,320		$ 7,797
Less: Accumulated depreciation and amortization	(2,154)		(2,154)		(937)
Property, plant and equipment , net	7,166		7,166		6,860
Depreciation and amortization expense	402	$ 107	1,217	$ 191
Construction in progress
Property, plant and equipment, net
Property, plant and equipment , gross	1,363		1,363		1,217
Plant and laboratory equipment
Property, plant and equipment, net
Property, plant and equipment , gross	4,784		4,784		3,669
Leasehold improvements
Property, plant and equipment, net
Property, plant and equipment , gross	785		785		532
Computer equipment
Property, plant and equipment, net
Property, plant and equipment , gross	1,667		1,667		1,658
Office equipment
Property, plant and equipment, net
Property, plant and equipment , gross	$ 721		$ 721		$ 721

Accrued expenses and other cu_3

Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Accrued expenses and other current liabilities
Accrued research and development costs	$ 3,714	$ 2,009
Accrued compensation and benefits costs	2,638	2,065
Accrued professional fees	363	779
Other	519	303
Total	$ 7,234	$ 5,156

Long-term debt (Details)

Long-term debt (Details) $ in Thousands	Mar. 31, 2020USD ($)
Long-term debt
Principal amount of long-term debt	$ 10,000
Unamortized debt discount	(199)
Long-term debt, net of discount	$ 9,801

Long-term debt - Hercules Loan

Long-term debt - Hercules Loan Agreement (Details) - USD ($) $ in Thousands	Dec. 15, 2020	Jun. 01, 2020	Aug. 08, 2019	Dec. 31, 2020	Dec. 31, 2020	Oct. 01, 2020	May 31, 2020	Mar. 31, 2020	Aug. 31, 2019
Debt Securities
Loss on extinguishment of debt				$ (913)	$ (913)
Interest expense				247	817
Debt discount								$ 199
Hercules Loan Agreement
Debt Securities
Maximum borrowing capacity			$ 30,000
Borrowed amount			10,000
Payment of issuance costs			225
Additional closing and legal fees			$ 130
Loss on extinguishment of debt	$ 913
Total paid amount	10,839
Outstanding principal	10,000
Term charge	495
Termination fee due	300
Accrued interest	44
Upfront fees, including closing costs and legal fees									$ 355
Interest expense				247	817
Non-cash interest expense related to accretion of the debt discount				55	181
Accretion of the debt discount				26	82
Accretion of the final payment				29	99
Principal payments due or paid	$ 10,000
Hercules first amendment
Debt Securities
Maximum borrowing capacity		$ 40,000					$ 30,000
Closing and legal fees will be capitalized and amortized		100
Additional closing and legal fees		$ 100
Upfront fees, including closing costs and legal fees				$ 100	$ 100
Hercules loan agreement, second advance
Debt Securities
Maximum borrowing capacity						$ 10,000

Stockholders' equity (Details)

Stockholders' equity (Details) - $ / shares	Dec. 31, 2020	Mar. 31, 2020
Stockholders' Equity
Shares authorized (in shares)	150,000,000	150,000,000
Par value (in dollars per share)	$ 0.001	$ 0.001
Undesignated preferred stock, authorized	10,000,000
Preferred stock, Par Value (in dollars per share)	$ 0.001
Undesignated preferred shares issued	0
Undesignated preferred shares outstanding	0
Employees stock options
Stockholders' Equity
Common stock reserved for issuance	14,753,921	10,449,033

Stockholders' equity - Converti

Stockholders' equity - Convertible preferred stock and preferred stock warrants (Details) $ / shares in Units, $ in Thousands	Jul. 25, 2018$ / sharesshares	Jul. 09, 2018	Dec. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2020USD ($)
Convertible preferred stock
Forward stock split ratio for each common stock		0.100534
Preferred stock outstanding | $			$ 0	$ 0
Number of stock warrants issued			5,284,238
Common stock
Convertible preferred stock
Conversion of shares (in shares)	19,157,360
Series seed preferred stock
Convertible preferred stock
Number of stock warrants issued			50,000
Exercise price (in dollars per share) | $ / shares			$ 10
Initial public offering | Series seed preferred stock
Convertible preferred stock
Exercise price (in dollars per share) | $ / shares	$ 1.01
Number of warrants became exercisable	497,344
Warrants outstanding			497,344

Stockholders' equity - ATM Prog

Stockholders' equity - ATM Program (Details) - USD ($) $ / shares in Units, $ in Thousands	Aug. 11, 2020	Oct. 31, 2020	Jun. 30, 2020	Dec. 31, 2019	Aug. 31, 2019	Dec. 31, 2020	Mar. 31, 2020
Class of Warrant or Right [Line Items]
Common stock, par value (in dollars per share)						$ 0.001	$ 0.001
Net proceeds		$ 269,975	$ 107,782	$ 85,598
ATM sales
Class of Warrant or Right [Line Items]
Percentage Of Commission	3.00%
Shares issued during period						0	287,559
Gross proceeds							$ 4,568
Legal fees							137
Net proceeds							$ 4,431
ATM sales | Common stock
Class of Warrant or Right [Line Items]
Aggregate offering amount	$ 350,000
Common stock, par value (in dollars per share)	$ 0.001				$ 0.001
ATM sales | Common stock | Maximum
Class of Warrant or Right [Line Items]
Aggregate offering amount	$ 62,500		$ 30,000		$ 75,000

Stockholders' equity - Equity o

Stockholders' equity - Equity offerings (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				9 Months Ended
	Oct. 31, 2020	Jun. 30, 2020	Dec. 31, 2019	Nov. 30, 2019	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Net proceeds from issuance after deducting underwriting discounts, commissions and other offering expenses	$ 269,975	$ 107,782	$ 85,598
Underwriting discounts, commissions and other offering expenses	$ 17,525		$ 5,814		$ 100	$ 355
Number of common stocks are exercisable from the November 2019 Pre-Funded Warrants and the June 2020 Pre-Funded Warrants					5,284,238
Pre-Funded Warrants
Class of Warrant or Right [Line Items]
Issuance of pre-funded warrants (in shares)	1,562,500	1,521,738		2,200,000
Public offering price	$ 39.99
Pre-funded warrants exercise price		$ 22.9999		$ 13.6099
Variation between public offering prices of common stock and Pre-Funded Warrants	$ 0.0001	$ 0.0001		$ 0.0001
Shares issued during period	937,500
Maximum percentage of holding for exercise warrants	9.99%	9.99%		9.99%
Prior notice period to change percentage of holding	61 days	61 days
Maximum percentage of increase (decrease) of holding for exercise warrants	19.99%	19.99%
Underwriter rights
Class of Warrant or Right [Line Items]
Number of shares issued	5,625,000	2,826,088	838,530	3,678,031
Public offering price	$ 40	$ 23		$ 13.61
Shares issued during period		652,173
Underwriting discounts, commissions and other offering expenses		$ 7,217

Stock-based compensation (Detai

Stock-based compensation (Details) - shares	Apr. 01, 2020	Apr. 01, 2019	Jul. 09, 2018	Apr. 30, 2020	Dec. 31, 2020	Mar. 31, 2020
2017 Plan
Share based payments
Shares authorized (in shares)					2,659,885
Number of shares available for grant			2,520,247		0
2018 Plan
Share based payments
Shares authorized (in shares)			3,617,968
Number of shares available for grant					1,613,894
Additional shares authorized (in shares)		1,266,278		1,466,749
ESPP
Share based payments
Additional shares authorized (in shares)	366,687	316,569	697,224
Common stock reserved for issuance	1,031,868		348,612
Share based payment award percentage of outstanding shares			1.00%
Employees stock options
Share based payments
Exercise price for persons holding ten percent of voting power (as a percent)					100.00%
Exercise price for persons holding more than ten percent of voting power (as a percent)					110.00%
Share based payment award expiration period					10 years
Share based payment award vesting period					4 years
Common stock reserved for issuance					14,753,921	10,449,033
Employees stock options | Minimum
Share based payments
Expiration period for persons holding more than ten percent of voting power					10 years
Employees stock options | Maximum
Share based payments
Expiration period for persons holding ten percent of voting power					5 years

Stock-based compensation - Assu

Stock-based compensation - Assumptions to determine grant-date fair value of stock options (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Stock-based compensation
Risk-free interest rate	0.31%	1.68%	1.01%	2.17%
Expected term (in years)	6 years 1 month 6 days	6 years 1 month 6 days	6 years 4 months 24 days	6 years
Expected volatility	76.30%	69.70%	74.80%	71.00%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Stock-based compensation - Stoc

Stock-based compensation - Stock option activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Number of Shares
Outstanding at beginning of the period (in shares)			4,964,381
Granted (in shares)			2,284,004
Exercised (in shares)			(612,671)
Cancelled (in shares)			(309,137)
Outstanding at end of the period (in shares)	6,326,577		6,326,577		4,964,381
Options exercisable (in shares)	2,617,429		2,617,429		2,117,721
Weighted Average Exercise Price
Outstanding at beginning of the period (in dollars per share)			$ 9.78
Granted (in dollars per share)			15.24
Exercised (in dollars per share)			8.01
Cancelled (in dollars per share)			12.59
Outstanding at end of the period (in dollars per share)	$ 11.79		11.79		$ 9.78
Options exercisable (in dollars per share)	$ 7.82		$ 7.82		$ 5.66
Weighted Average Contractual Term (Years)
Outstanding (years)			8 years 15 days		8 years 7 days
Granted (years)			9 years 4 months 13 days
Exercised (years)			6 years 9 months 15 days
Options exercisable (years)			6 years 10 months 28 days		7 years 2 months 12 days
Aggregate Intrinsic Value
Outstanding at beginning of the period			$ 15,345
Outstanding at end of the period	$ 167,873		167,873		$ 15,345
Options exercisable	79,395		$ 79,395		$ 11,733
Weighted average grant-date fair value per share of stock options granted			$ 10.06	$ 9.63
Total fair value of options vested	$ 2,069	$ 1,063	$ 8,330	$ 4,480

Stock-based compensation - Clas

Stock-based compensation - Classification of expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Share-Based Compensation
Share-based Compensation	$ 3,049	$ 2,344	$ 8,318	$ 5,935
Total unrecognized compensation cost	31,002		$ 31,002
Expenses expected to be recognized over a weighted average remaining period			2 years 11 months 12 days
Research and development expenses
Share-Based Compensation
Share-based Compensation	1,454	1,318	$ 3,750	2,974
General and administrative expenses
Share-Based Compensation
Share-based Compensation	$ 1,595	$ 1,026	$ 4,568	$ 2,961

Net loss per share (Details)

Net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net loss attributable to common stockholders	$ (21,783)	$ (16,189)	$ (59,371)	$ (36,836)
Denominator:
Weighted average common shares outstanding, basic and diluted (in shares)	49,382,213	34,877,944	44,436,680	32,742,148
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.44)	$ (0.46)	$ (1.34)	$ (1.13)

Net loss per share - Computatio

Net loss per share - Computation of diluted net loss per share attributable to common stockholders (Details) - shares	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Diluted net loss per share attributable to common stockholders
Antidilutive securities excluded from computation of diluted weighted average shares outstanding	6,823,921	5,413,746	6,823,921	5,413,746
Options to purchase common stock
Diluted net loss per share attributable to common stockholders
Antidilutive securities excluded from computation of diluted weighted average shares outstanding	6,326,577	4,916,402	6,326,577	4,916,402
Warrants to purchase convertible preferred stock
Diluted net loss per share attributable to common stockholders
Antidilutive securities excluded from computation of diluted weighted average shares outstanding	497,344	497,344	497,344	497,344

Significant agreements (Details

Significant agreements (Details) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2020item	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Mar. 31, 2020USD ($)
Significant agreements
Prepaid expenses and other current assets		$ 4,035		$ 4,035		$ 2,734
Regeneron Pharmaceuticals, Inc
Significant agreements
Payments received under the terms of the agreement		1,453	$ 760	3,857	$ 2,008
Prepaid expenses and other current assets		$ 1,195		$ 1,195		$ 971
Bristol-Myers Squibb Company
Significant agreements
Number Of Patients | item	125

Commitments and contingencies -

Commitments and contingencies - Lease agreements (Details) $ in Thousands	Dec. 25, 2020USD ($)	Jun. 29, 2020USD ($)	Jun. 24, 2020USD ($)	Jun. 23, 2020USD ($)	Oct. 22, 2019USD ($)ft²	Aug. 01, 2019USD ($)ft²	Jun. 30, 2019USD ($)ft²	Jun. 30, 2018USD ($)ft²Option	Apr. 30, 2016	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Mar. 31, 2020USD ($)
Lease agreements
Increase of lease liability and right-of-use asset from lease modification		$ 1,580
Prior notice period upon termination of lease									12 months
Base rent of monthly lease payments	$ 29		$ 14	$ 29
Reclassified from prepaid rent					$ 18,164	$ 2,368
Leased office space | ft²					52,500	10,500	18,700	63,000
Prepaid Rent					$ 261
Lease term							10 years	10 years
Number of options to renewal the lease | Option								2
Renewal period of lease							5 years	5 years
Annual rental payment							$ 488	$ 2,373
Percentage of annual increase in lease rental expenses							1.60%	3.00%
Property, plant and equipment, net										$ 7,166		$ 7,166		$ 6,860
Right-to-use asset							$ 4,363			5,839		5,839		$ 4,425
Right-to-use liability							$ 4,363			6,135		6,135
Finance lease costs										607	$ 607	1,821	$ 666
General and administrative expenses
Lease agreements
Finance lease costs										90	90	268	149
Research and development expenses
Lease agreements
Finance lease costs										$ 518	$ 517	$ 1,553	$ 517

Commitments and contingencies_2

Commitments and contingencies - Components of lease expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Finance lease costs:
Amortization of right-of-use assets	$ 607	$ 607	$ 1,821	$ 666
Interest on lease liabilities		591		652
Interest on lease liabilities	560	834	1,683	1,029
Operating lease costs	239	262	705	633
Total lease cost	$ 1,406	$ 1,460	$ 4,209	$ 1,951

Commitments and contingencies_3

Commitments and contingencies - Future lease payments under operating and financing lease liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2019
Operating lease
2021 (remaining three months)	$ 240
2022	967
2023	976
2024	986
2025	995
Thereafter	5,054
Total lease payments	9,218
Less: interest	3,083
Total lease liabilities	6,135	$ 4,363
Financing lease
2021 (remaining three months)	611
2022	2,487
2023	2,562
2024	2,639
2025	2,718
Thereafter	43,704
Total lease payments	54,721
Less: interest	27,437
Total lease liabilities	27,284
Total
2021 (remaining three months)	851
2022	3,454
2023	3,538
2024	3,625
2025	3,713
Thereafter	48,758
Total lease payments	63,939
Less: interest	30,520
Total lease liabilities	$ 33,419

Commitments and contingencies_4

Commitments and contingencies - Additional information related to leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020	Jun. 30, 2019
Leases
Right-to-use operating lease asset	$ 5,839		$ 4,425	$ 4,363
Right-to-use finance lease asset	45,129		46,925
Total lease assets	50,968		51,350
Operating lease liabilities, current	965		873
Finance lease liabilities, current	2,469		2,411
Operating lease liabilities, non-current	5,170		3,737
Financing lease liabilities, non-current	24,815		24,967
Total lease liabilities	33,419		$ 31,988
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	582	$ 516
Operating cash flows from finance leases	1,682	623
Financing cash flows from finance leases	92	22
Right-to-use asset obtained in exchange for new operating lease liabilities	$ 1,580	$ 5,152
Weighted-average remaining lease term - operating leases	9 years 1 month 6 days	8 years 7 months 6 days
Weighted-average remaining lease term - financing leases	18 years 7 months 6 days	19 years 7 months 6 days
Weighted-average discount rate - operating leases	9.80%	7.00%
Weighted-average discount rate - financing leases	8.30%	8.00%

Commitments and contingencies_5

Commitments and contingencies - Manufacturing commitments (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Mar. 31, 2020
Commitments and contingencies
Minimum payments committed to manufacturing organization	$ 1,622	$ 3,569

Geographic information (Details

Geographic information (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2020USD ($)segment	Mar. 31, 2020USD ($)
Geographic information
Number of operating geographic regions | segment	2
Long-lived assets	$ 7,166	$ 6,860
United States
Geographic information
Long-lived assets	6,564	6,357
United Kingdom
Geographic information
Long-lived assets	$ 602	$ 503

Uncategorized Items - repl-2020

Label	Element	Value
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 64,638,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 326,111,000